Premium
Hollow Au–Cu Nanocomposite for Real‐Time Tracing Photothermal/Antiangiogenic Therapy
Author(s) -
Pang Xiaojuan,
Tan Xiaoxiao,
Wang Jinping,
Liu Li,
You Qing,
Sun Qi,
Wang Yidan,
Tan Fengping,
Li Nan
Publication year - 2017
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201700099
Subject(s) - photothermal therapy , materials science , biophysics , fluorescence , absorption (acoustics) , surface plasmon resonance , cancer cell , flow cytometry , förster resonance energy transfer , nanotechnology , cancer research , biomedical engineering , cancer , microbiology and biotechnology , nanoparticle , medicine , biology , optics , physics , composite material
High absorption in the near‐infrared (NIR) region is essential for a photoabsorbing agents to realize efficient photothermal therapy (PTT) for cancer. Here, a novel hollow Au–Cu nanocomposite (HGCNs) is developed, which displays a significantly enhanced NIR surface plasmon resonance absorption and photothermal transduction efficiency. Besides, fluorescent polymer dots poly(9,9‐dioctylfluorene‐2,7‐diyl‐ co ‐benzothiadiazole) (PFBT) and chemotherapeutic mammalian target of rapamycin (mTOR) inhibitor agent rapamycin (RAPA) are attached onto the HGCNs (RAPA/PFBT‐HGCNs) for real‐time NIR fluorescence tracing and combined PTT/antiangiogenesis therapy. In particular, due to the fluorescence resonance energy transfer effect, RAPA/PFBT‐HGCNs can act as NIR‐activatable on/off probe system for real‐time tracing of tumor tissues. A standard in vitro cellular uptake study, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay, dual‐staining study, and flow cytometry assay reveal that the RAPA/PFBT‐HGCNs combined with NIR laser exhibit higher drug accumulation and cytotoxicity in both tumor cells and epithelial cells. Moreover, the margins of tumor and normal tissue can be accurately indicated by NIR‐stimulated dequenched PFBT after 24 h intravenous administration. Further, tumor growth can be considerably hampered by the optimal formulation plus laser treatment with relatively lower side effects. Consequently, the work highlights the real‐time tracing and enhanced PTT/antiangiogenesis therapy prospects of the established HGCNs with tremendous potential for treatment of cancer.